Transcriptomic Profiling of Carboplatin- and Paclitaxel-Resistant Lung Adenocarcinoma Cells Reveals CSF3 as a Potential Biomarker for the Carboplatin Plus Paclitaxel Doublet Regimens
Open Access
- 11 December 2024
- journal article
- research article
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 46 (12) , 13951-13969
Abstract
This study aimed to generate Car- and Pac-resistant cell lines from the human lung adenocarcinoma H1792 cell line, designated as H1792/Car and H1792/Pac, and perform transcriptome sequencing to identify potential targets. Common differentially expressed genes (Co-DEGs) in both resistant cell lines were identified, followed by hub gene identification. Online validation was conducted through GEPIA and Kaplan–Meier Plotter platforms, with experimental validation performed using real-time quantitative PCR (RT-qPCR). After six months, the H1792/Car and H1792/Pac cell lines exhibited a 10.7-fold and 5.6-fold increase in resistance to Car and Pac, respectively. Flow cytometry analysis demonstrated that both resistant cell lines were resistant to cell cycle arrest and apoptosis induced by Car or Pac. Transcriptomic sequencing identified 123 Co-DEGs, including 72 upregulated and 51 downregulated genes, consistently expressed in both H1792/Car and H1792/Pac cell lines. Among these, 13 hub genes were identified, with colony-stimulating factor 3 (CSF3) uniquely associated with post-progression survival (PPS) in adenocarcinoma patients undergoing chemotherapy. Notably, CSF3 expression was significantly elevated in both H1792/Car and H1792/Pac compared to parental cells. These findings underscore the value of drug-resistant models in uncovering critical biomarkers. CSF3 emerges as a promising guiding marker or potential molecular target for optimizing Car- and Pac-based doublet regimens.Keywords
Funding Information
- The National Science, Research and Innovation Fund (NSRF) and Prince of Songkla University (MED6505175S, MR PSU663823029)
- Faculty of Medicine, Prince of Songkla University (MED6505175S, MR PSU663823029)
This publication has 31 references indexed in Scilit:
- G-CSF improving combined whole brain radiotherapy and immunotherapy prognosis of non-small cell lung cancer brain metastasesInternational Immunopharmacology, 2024
- Carboplatin-induced upregulation of pan β-tubulin and class III β-tubulin is implicated in acquired resistance and cross-resistance of ovarian cancerCellular and Molecular Life Sciences, 2023
- Two decades of pegfilgrastim: what have we learned? Where do we go from here?Current Medical Research and Opinion, 2023
- Transcriptome analysis of newly established carboplatin-resistant ovarian cancer cell model reveals genes shared by drug resistance and drug-induced EMTBritish Journal of Cancer, 2023
- RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer TreatmentDiscover Oncology, 2018
- G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancerOncoImmunology, 2015
- G-CSF and G-CSFR are highly expressed in human gastric and colon cancers and promote carcinoma cell proliferation and migrationBritish Journal of Cancer, 2014
- G-CSF induces a potentially tolerant gene and immunophenotype profile in T cells in vivoClinical Immunology, 2009
- Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinomaCancer, 1998
- Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factorNature, 1986